• Technology Profile
• Glycobiology
• Marine Natural Products
• Pipeline
• Partnering

Research & Development

Marine Natural Products

Historically, terrestrial natural products have been a premier source for commercially successful drugs such as Aspirin, penicillin, and Taxol.

Recently, however, there have been diminishing returns from attempts to further exploit terrestrial sources and with the lack of new hits generated from computational approaches, attention has increasingly turned to the marine environment.

Marine organisms have developed unique metabolic and physiological capabilities that ensure survival in diverse habitats, and have resulted in the evolution of an array of secondary metabolites and unique chemistry. Several compounds have been developed commercially, with many others identified and also now in drug development pipelines.

GlycoMar specialises in the isolation and purification of products from marine organisms, excluding mammals. Species are selected for their potential to provide novel compounds, and for their availability and future sustainability. GlycoMar is the only company dedicated to the isolation and characterisation of novel glycobiology products from marine organisms.

Glycosaminoglycans

GlycoMar is developing a range of glycosaminoglycans from marine invertebrates. These are being evaluated for a number of applications, including anti-inflammatory Research & Development.

Glycoproteins

GlycoMar is currently developing a group of mucin-type glycoproteins from marine invertebrates. These are being evaluated as anti-inflammatories.

Enzymes

GlycoMar is developing diagnostic enzymes from marine bacteria and marine invertebrates.